Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA gptkb:EMA August 2020 |
| gptkbp:ATCCode |
L04AA44
|
| gptkbp:CASNumber |
679818-59-8
|
| gptkbp:contraindication |
active infection
hypersensitivity to ofatumumab |
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:form |
pre-filled pen
pre-filled syringe |
| gptkbp:genericName |
gptkb:ofatumumab
|
| gptkbp:halfLife |
16 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kesimpta
|
| gptkbp:indication |
relapsing forms of multiple sclerosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
anti-CD20 monoclonal antibody
|
| gptkbp:pregnancyCategory |
N
B1 not recommended |
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:PubChem_CID |
DB06650
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
headache
injection site reaction upper respiratory tract infection |
| gptkbp:target |
gptkb:CD20
|
| gptkbp:UNII |
6G8NSG6K5V
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|